Sequential patch testing in a patient treated with dupilumab then with upadacitinib: Differences in patch test results as well as in disease control

Mainville, Laurence; Veillette, Hélène; Houle, Marie‐Claude

doi:10.1111/cod.14278

Cited by 8 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Records found for a total of 67 patients with or without concomitant AD that were refractory to topical and systemic steroids as well as other systemic immunosuppressants and subsequently treated with dupilumab showed complete or partial responses in 65/67 patients ( Table 1 ) [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ]. In two cases, no effects of dupilumab were reported [ 60 , 61 ]. Interestingly, some reports demonstrated clinical remissions under dupilumab when allergen or irritant avoidance was not feasible.…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…• Omalizumab: no hemos encontrado estudios asociados al PT pero, por su mecanismo de acción, no debería interferir en los resultados del mismo [21][22][23][24][25][26][27][28] .…”

Section: ¿Se Les Pueden Poner Parches a Los Pacientes Que Están En Tr...unclassified

Controversias en dermatitis alérgica por contacto

La Forgia,

Infante,

Bassotti

et al. 2023

Dermatol. Argent.

View full text Add to dashboard Cite

El abordaje de la dermatitis alérgica por contacto plantea controversias en ciertas poblaciones como en los niños y en pacientes en tratamiento con inmunosupresores o biológicos. El posible beneficio resultante de la realización de pruebas epicutáneas amerita que, sin minimizar el desafío, se evalúe cada caso a la luz de la evidencia actual. En base a nuestra experiencia clínica y la revisión de la literatura podemos, además, encontrar respuestas frente a la descalificación de preservantes como los parabenos o frente a la sobrevaloración de los productos “naturales”.

show abstract

Toward a Molecular Diagnosis: Looking Under the Skin at Allergic Contact Dermatitis

Bahamon,

Strassner,

2023

Curr Derm Rep

View full text Add to dashboard Cite

Sequential patch testing in a patient treated with dupilumab then with upadacitinib: Differences in patch test results as well as in disease control

Cited by 8 publications

References 3 publications

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Controversias en dermatitis alérgica por contacto

Toward a Molecular Diagnosis: Looking Under the Skin at Allergic Contact Dermatitis

Contact Info

Product

Resources

About